Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
top of page
Browse by category
Search
Novo Nordisk to enter RNA market with Dicerna purchase
Denmark's Novo Nordisk, the world's leading insulin maker, has revealed it will buy US-based Dicerna Pharmaceuticals, a developer of RNA...
FDA approves Novo Nordisk’s Wegovy (semaglutide 2.4 mg) for weight management
The FDA has approved Novo Nordisk’s Wegovy (the brand name for once-weekly semaglutide 2.4mg injection in the US) for chronic weight...
Browse by tag
bottom of page